We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the ...

Just nine months after announcing a massive plan to cut costs, Bristol Myers Squibb has gone one better, revealing a new goal ...

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 150 points on Thursday. The Dow ...

Operator Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this event is being recorded. I would now like to turn the conference ...

BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics towards the end of 2023, and analysts at ...

The ERISA Industry Committee, along with two other industry groups, is seeking the dismissal of the drugmaker’s PRT ...

If we get robust job growth with higher wages ... I think you should consider building a position for Bristol-Myers Squibb, which happens to be the newest position of my Charitable Trust ...

In an amicus brief, several advocacy groups warned that letting the lawsuit proceed past a motion to dismiss could open the ...

Bristol Myers Squibb Co. released sales and profit forecasts for 2025 below Wall Street’s expectations — a sign the company’s ...

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in ...